Fundz

Mallinckrodt Appoints Dr. Marek J. Honczarenko as Chief Scientific Officer

PRIVATESep 22, 2025

Position

Executive Vice President

Company

Mallinckrodt

Marek J. Honczarenko
ManufacturingBiotechnologyHealth CarePharmaceutical

Description

Mallinckrodt plc has appointed Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer, effective September 29, 2025

Quick answer

Mallinckrodt Appoints Dr. Marek J. Honczarenko as Chief Scientific Officer (September 22, 2025).

Who is the new Executive Vice President at Mallinckrodt?
Mallinckrodt named Marek J. Honczarenko Executive Vice President, announced September 22, 2025.
What did Mallinckrodt announce on September 22, 2025?
Mallinckrodt plc has appointed Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer, effective September 29, 2025
What does Mallinckrodt do?
Mallinckrodt is a global specialty pharmaceutical company consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.
Which similar companies made leadership changes around the same time?
GSK plc (September 29, 2025), Halozyme Therapeutics (October 6, 2025), Helus Pharma (September 2, 2025) and Eli Lilly and Company (October 16, 2025) also announced leadership changes within 45 days of Mallinckrodt.

Source: Fundz verified event record.

Other recent leadership changes in Pharmaceutical and Manufacturing

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Mallinckrodt, and when

A new leader at Mallinckrodt brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Mallinckrodt raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Mallinckrodt, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Mallinckrodt. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Mallinckrodt

About

Mallinckrodt is a global specialty pharmaceutical company consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Mallinckrodt changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Mallinckrodt's next move

Learn about Strategic plan

Mallinckrodt changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.